Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

ALKS 32.17 -1.14 (-3.42%)
price chart
Alkermes Plc Ord (NASDAQ:ALKS) Short Interest Increased By 33.39%
The stock of Alkermes Plc Ord (NASDAQ:ALKS) registered an increase of 33.39% in short interest. ALKS's total short interest was 4.70M shares in February as published by FINRA.
DIAM Co. Ltd. Reduces Stake in Alkermes Plc (ALKS)  Financial Market News
Buzzing Stock : Alkermes plc (NASDAQ:ALKS)?  Vanguard Tribune
What after Mitchell Paul J's Insider Sale of Alkermes Plc (NASDAQ:ALKS) Stock?
As announced in a legal document which was filled with the SEC on February 4, 2016, Mitchell Paul J an insider in Alkermes Plc., sold shares worth $65,620 U.S Dollars in the stock exchange listed company. Mitchell Paul J disposed 2,000 new shares, ...
Insider Selling: Alkermes Plc (ALKS) Director Sells 2000 Shares of Stock  Financial Market News
Alkermes plc (NASDAQ:ALKS): Sell-side Look at Earnings  Uptick Analyst
Alkermes Plc.: Invesco Ltd Opened Big New Position
Latest Security and Exchange filings show 252 investors own Alkermes Plc.. The institutional ownership in Q3 2015 is very high, at 102.00% of the outstanding shares.
Alkermes Plc (ALKS) Stake Boosted by California State Teachers Retirement System  Financial Market News
American Century Companies Inc. Has $1121000 Stake in Alkermes Plc (ALKS)  Daily Political
Alkermes plc (ALKS) Hits Milestones in CNS Product and Pipeline Portfolio
Alkermes plc (NASDAQ: ALKS) today announced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Announces Achievement of Milestones for CNS Medicines in ...  Business Wire (press release)
Alkermes Plc (ALKS) Downgraded by JPMorgan Chase & Co.
Alkermes Plc (NASDAQ:ALKS) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report released on Thursday, The Fly reports.
Alkermes Stock Tanks After Depression Drug Fails Late Stage Trials  Bidness ETC
Will Alkermes Plc Recover From High Profile Failures?  Business Finance News
Alkermes plc Reports Third Quarter 2015 Financial Results
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes plc (ALKS) Tops Q3 EPS by 3c  StreetInsider.com
Healthcare Sector For Investors: Alkermes Plc (NASDAQ:ALKS), Allergan PLC ...  News Oracle
Analysts Estimations- Alkermes Plc
The shares of Alkermes Plc (NASDAQ:ALKS) currently has mean rating of 2.45 while 2 analysts have recommended the shares as “BUY”, 3 recommended as “OUTPERFORM” and 5 recommended as “HOLD”.
Alkermes plc Announces Sale of Gainesville, GA Manufacturing Facility to Recro ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ:ALKS) today announced that it has entered into a definitive agreement to sell its manufacturing facility in Gainesville, GA, the manufacturing and royalty revenue associated with products manufactured at ...
Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP ...  GlobeNewswire (press release)
Alkermes to Sell Georgia Facility, Pain-Drug Rights to Recro Pharma  Wall Street Journal
Capstone Asset Management Company Acquires 690 Shares of Alkermes Plc (ALKS)
Alkermes Plc logo Capstone Asset Management Company raised its stake in shares of Alkermes Plc (NASDAQ:ALKS) by 15.1% during the fourth quarter, according to its most recent 13F filing with the SEC.
FY2018 Earnings Estimate for Alkermes Plc (ALKS) Issued By Jefferies Group  IRA Market Report
Leerink Swann Reaffirms "Buy" Rating for Alkermes Plc (ALKS)  Corvus Business Newswire
Alkermes plc (ALKS) is Trading Lower on Unusual Volume for January 18
Alkermes plc (ALKS) experienced unusually high volume on Jan. 18, as the stock lost 3.56% to a closing price of $62.36. The stock saw 2.34 million shares trade hands over the course of the day on 17,999 trades.